Seersholm et al9 | 1997 | Observational cohort, concurrent controls | FEV1 decline | In patients with FEV1 31–65% augmentation slowed decline of FEV1 by 21 ml/year |
NHLBI Registry7 | 1998 | Observational cohort, concurrent controls | FEV1 decline and survival | In patients with FEV1 35–49% augmentation slowed decline of FEV1 by 27 ml/year. Risk ratio for death with augmentation 0.64 compared with non-recipients |
Dirksen et al8 | 1999 | Randomised controlled trial | FEV1 decline lung density (CT) | Loss of lung tissue 2.6 g/l/year with placebo and 1.5 g/l/year with augmentation |
Gottlieb et al12 | 2000 | Descriptive | Urinary desmosine | Augmentation did not reduce the rate of elastin degradation |
Lieberman11 | 2000 | Observational (web based survey) | Frequency of lung infections | Number of lung infections per year decreased from 3–5 before augmentation to 0–1 after augmentation |
Wencker et al10 | 2001 | Observational (before–after) | FEV1 decline | Rates of FEV1 decline before and after augmentation 49.2 and 34.2 ml/year. Respectively |
Stockley et al13 | 2002 | Descriptive | Sputum inflammatory markers | Augmentation reduced sputum leukotriene B4 |